FluidForm
FluidForm develops FRESH bioprinting technology enabling 3D printing of complex soft tissues and organs for regenerative medicine.
- CEO / Founder
- Michael Graffeo
- Team Size
- 20
- Stage
- Active
- Total Funding
- $5M
- Latest Round
- Crowdfunding
- Key Investors
- 1945 Capital, Hackensack Meridian Health, U.S. Department of Health and Human Services, NSF, Mountain State Capital
Technology & Products
Key Products
LifeSupport bioprinting gel, FRESH bioprinting protocol licensing, Research collaboration services
Technological Advantage
Patented FRESH (Freeform Reversible Embedding of Suspended Hydrogels) technology from Carnegie Mellon
Differentiation
Value Proposition
FRESH technology enables bioprinting of soft tissues that maintain their shape during printing using gel support bath.
How They Differentiate
Unique gel support enables soft tissue geometries impossible with standard bioprinting approaches
Market & Competition
Target Customers
Research institutions, pharmaceutical companies, tissue engineering labs, medical device companies
Industry Verticals
Life Sciences, Tissue Engineering, Drug Discovery, Regenerative Medicine
Competitors
CELLINK/Cytiva, Organovo, Allevi/3D Systems
Growth & Milestones
Growth Metrics
$14.5M total funding raised since 2018; $4.5M raised in 2024; 2025 crowdfunding campaign on StartEngine at $25M valuation cap; Revenue $168K (R&D stage company)
Major Milestones
2018: Founded in Waltham, MA; Developed FRESH 3D bioprinting platform; Raised seed funding from 1945 Capital; 2024: Raised $4.5M; 2025-04: Launched $1.24M StartEngine crowdfunding; 2025-07: Presented 6-month efficacy data at IPITA and ADA conferences
Notable Customers
Research institutions, Pharmaceutical companies developing cell therapies, Academic collaborators in regenerative medicine